XyloCor chooses Indegene's MME to assess PRMA landscape for refractory angina | Videos | What We Think | Indegene

#FutureReadyHealthcare

Who We Are

Investor Relations

Careers

XyloCor chooses Indegene's MME to assess PRMA landscape for refractory angina

Related Insights

Cosette Pharmaceuticals chooses Indegene’s MME to assess market for 8 new cardiovascular therapies

4:05

Cosette Pharmaceuticals chooses Indegene’s MME to assess market for 8 new cardiovascular therapies

Webinar: The Metaverse - What it means for life sciences companies

1:01:37

Webinar: The Metaverse - What it means for life sciences companies

Learnings from MAPS 2022 Global Annual Meeting

7.01

Learnings from MAPS 2022 Global Annual Meeting

Let’s partner for #FutureReadyHealthcare

© 2023 Indegene. All Rights Reserved.

Privacy Policy CSR Policy Other Policies Indegene Speak Up